Global Paediatric Hodgkin Lymphoma Market, By Type (Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma), Therapy Type (ChemotherapyImmunotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Paediatric Hodgkin Lymphoma Market Analysis and Size
The global paediatric hodgkin lymphoma market is expected to witness significant growth during the forecast period. The global paediatric hodgkin lymphoma market is majorly driven by high prevalence of hodgkin lymphoma, increases in number of promising pipeline drugs, high diagnostics rate and vulnerable paediatric population. Multiple treatment landscape and family history of ovarian cancer are considered positive indicators for the demand for novel ovarian cancer drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global paediatric hodgkin lymphoma market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Paediatric Hodgkin Lymphoma Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Abbvie, Inc (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Seagen, Inc (U.S.), ONO Pharmaceutical Co., Ltd. (Japan) |
|
Market Opportunities |
|
Market Definition
Paediatric hodgkin lymphoma is a serious and life-threatening cancer that belongs to the group of lymphomas developed from the specific type of white blood cells. It turns into cancerous effects and hence attacks their own cells. If Hodgkin’s disease occurs in children, it is called paediatric hodgkin lymphoma. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Paediatric Hodgkin Lymphoma Market Dynamics
Drivers
- Increasing Demand of Immunotherapy
The rising demand of immunotherapy is boosting the growth of the market. For instance, in 2020, Northwestern University published immunotherapy results stating that a brief course of immunotherapy resulted in complete and near complete remission in approximately two-thirds of previously untreated patients with classical hodgkin lymphoma. More than 35 percent of patients experienced complete disappearance of lymphoma with pembrolizumab, an immune checkpoint inhibitor. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Hodgkin Lymphoma
As per the records, in 2020, around 8,540 people (4,570 men and 3,970 women) in the U.S. will be diagnosed with Hodgkin lymphoma. The number of people diagnosed with this disease dropped by 1.4 % every year. Thus, it boosts the market growth.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global paediatric hodgkin lymphoma market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth. Many a times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health. Thus, this is an important restrain that needs to be taken care of.
This global paediatric hodgkin lymphoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global paediatric hodgkin lymphoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Paediatric Hodgkin Lymphoma Market Scope
The global paediatric hodgkin lymphoma market is segmented on the basis of type, therapy type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Classic Hodgkin Lymphoma
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Therapy Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Paediatric Hodgkin Lymphoma Market Regional Analysis/Insights
The global paediatric hodgkin lymphoma market is analyzed and market size insights and trends are provided by type, therapy type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global paediatric hodgkin lymphoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the well-developed regulatory framework, high demand of disease-specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure and increased patient awareness level, and high prevalence of Hodgkin lymphoma in paediatric patients.
Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Paediatric Hodgkin Lymphoma Market Share Analysis
The paediatric hodgkin lymphoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to paediatric hodgkin lymphoma market.
Key players operating in the global paediatric hodgkin lymphoma market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-
